Premium
Decreased serum aldolase B levels in patients with malignant tumors
Author(s) -
Asaka Masahiro,
Kimura Toshio,
Nishikawa Shuhji,
Miyazuki Tomotsu,
Alpert Elliot
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19881215)62:12<2554::aid-cncr2820621217>3.0.co;2-x
Subject(s) - aldolase a , aldolase b , fructose bisphosphate aldolase , medicine , radioimmunoassay , cancer , fructose , isozyme , endocrinology , gastroenterology , enzyme , biochemistry , biology
Serum aldolase B levels were determined in patients with malignant tumors using a radioimmunoassay method. Thirty‐one of 52 patients with malignant tumors had decreased serum aldolase B levels of less than 20 ng/ml, whereas almost all of the normal subjects and the patients with liver diseases and other benign diseases showed serum aldoiase B levels of more than 20 ng/ml. The decreased aldolase B levels observed in cancer patients were unrelated to the clinical stage of their disease. The decrease of aldolase B correlated well with the decrease of fructose‐1‐phosphate (FlP)‐aldolase activity, but not with fructose‐1,6‐diphosphate (FDP)‐aldolase activity in the sera of cancer patients. Mixing experiments did not identify an inhibitor of aldolase B in sera of cancer patients. Furthermore, recovery of serum aldolase B levels after successful surgical resection in cancer patients suggested that the low levels of aldolase B in sera of cancer patients was not of genetic origin. The mechanism responsible for the decrease of aldolase B in sera of cancer patients is unclear.